Drugs / Glucagon
Glucagon
also known as
GlucaGen · G-Pen Mini · G-Pen · G-Pen (glucagon injection) · Lilly Glucagon · Xerisol Glucagon · Baqsimi · BC Glucagon · +16 more
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | BAQSIMI | — | 2025-03-17 | fda.gov ↗ |
| Label expansion | US (FDA) | GVOKE KIT | — | 2025-03-14 | fda.gov ↗ |
| Approved | EU (EMA) | Baqsimi | — | 2019-12-16 | europa.eu ↗ |
| Label expansions (4) | US (FDA) | GLUCAGON | — | 1979-11-27 – 2019-09-09 | fda.gov ↗ |
| Approved | US (FDA) | GLUCAGON | — | 1960-11-14 | fda.gov ↗ |
Trials 74 · started per year
today
US approved 1960
EU approved 2019
1
1
1
1
2
2
3
3
7
5
5
7
7
6
6
2
3
4
1
4
1
2
19591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT04712266 | Sep → Dec 2020 | type 1 diabetes mellitus | Abvance Therapeutics | Completed | No outcome recorded |
| Phase 0 | NCT04300049 | Feb 2018 → Nov 2023 | — | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 116 trials | ||||||
| Phase 1 | NCT06592261 | Sep 2024 → Aug 2026 overdue | hyperinsulinism, obesity disorder | Columbia University | Recruiting | No outcome recorded |
| Phase 1 | NCT06588504 | Sep 2024 → Jul 2025 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04992312 | Mar 2022 → Nov 2023 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04347252 | Sep 2019 → Apr 2021 | — | David D'Alessio, M.D. | Completed | No outcome recorded |
| Phase 1 | NCT03965130 | Jun 2019 → Jul 2022 | — | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT03424044 | Mar 2018 → May 2019 | type 1 diabetes mellitus | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 1 | NCT03339453 | Nov → Dec 2017 | hypoglycemia, type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03176524 | Jun → Sep 2017 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT02817659 | Nov 2016 → Jan 2017 overdue | obesity disorder | AdventHealth Translational Research Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02740829 | Mar 2015 → Jan 2016 | diabetes mellitus | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 1 | NCT02403648 | Nov 2014 → Mar 2015 | hypoglycemia | Biodel | Completed | No outcome recorded |
| Phase 1 | NCT01916265 | Aug → Nov 2013 | type 1 diabetes mellitus | Profil Institute for Metabolic Research GmbH | Completed | No outcome recorded |
| Phase 1 | NCT02778100 | Mar → Apr 2013 | common cold | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02778113 | Oct 2011 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT00817271 | Feb → Apr 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00304538 | Mar → Jul 2006 | type 1 diabetes mellitus | DiObex | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07300982 | Apr 2026 → Dec 2029 expected | diabetes mellitus | Duke University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06854861 | Apr → Nov 2025 | type 1 diabetes mellitus | St. Olavs Hospital | Suspended | No outcome recorded |
| Phase 1/2 | NCT05500586 | Oct 2022 → Sep 2025 | metabolic dysfunction-associated steatotic liver disease, obesity disorder, type 2 diabetes mellitus | Adrian Vella | Completed | No outcome recorded |
| Phase 1/2 | NCT03255629 | Sep 2017 → Aug 2018 | postgastrectomy syndrome | Joslin Diabetes Center | Completed | No outcome recorded |
| Phase 215 trials | ||||||
| Phase 2 | NCT05960565 | Dec 2023 | type 1 diabetes mellitus | St. Olavs Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT03841526 | Aug 2019 → Apr 2020 | hypoglycemia | Xeris Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03770637 | May 2019 → Feb 2020 | hyperinsulinemic hypoglycemia | Xeris Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03490942 | Mar 2018 → Nov 2019 | type 1 diabetes mellitus | Xeris Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02971228 | Nov 2016 → May 2017 | type 1 diabetes mellitus | Zealand Pharma | Completed | No outcome recorded |
| Phase 2 | NCT02937558 | Oct 2016 → Sep 2018 | congenital isolated hyperinsulinism | Xeris Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02733588 | Mar 2016 → Apr 2017 | hypoglycemia | Xeris Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02660242 | Jan 2016 → Feb 2017 | type 1 diabetes mellitus | Jaeb Center for Health Research | Completed | No outcome recorded |
| Phase 2 | NCT02411578 | Sep 2015 → Apr 2016 | type 1 diabetes mellitus | Jaeb Center for Health Research | Completed | No outcome recorded |
| Phase 2 | NCT02423980 | Apr → May 2015 | hypoglycemia | Xeris Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02081001 | Mar → Aug 2014 | hypoglycemia | Xeris Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02081014 | Mar → Nov 2014 | hypoglycemia | Xeris Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01556594 | Mar → Jul 2012 | hypoglycemia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00797823 | Nov 2008 → Sep 2009 | type 1 diabetes mellitus | Legacy Health System | Completed | No outcome recorded |
| Phase 2 | NCT00434772 | Dec 2007 → May 2009 | hypoglycemia | Shaare Zedek Medical Center | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT03650582 | Jun 2017 → Sep 2018 | obesity disorder | University Health Network, Toronto | Unknown | No outcome recorded |
| Phase 2/3 | NCT01997411 | Nov 2013 → Jan 2015 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 311 trials | ||||||
| Phase 3 | NCT03738865 | Sep 2018 → Mar 2019 | hypoglycemia, type 1 diabetes mellitus | Xeris Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03421379 | Feb → Aug 2018 | diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03216226 | Jun 2017 → Feb 2018 | hypoglycemia, type 1 diabetes mellitus | Zealand Pharma | Completed | No outcome recorded |
| Phase 3 | NCT03091673 | Mar → Sep 2017 | type 1 diabetes mellitus | Xeris Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02656069 | Mar → Aug 2017 | hypoglycemia, type 1 diabetes mellitus | Xeris Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02402933 | Mar → Aug 2015 | diabetes mellitus, hypoglycemia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02171130 | May 2014 → Aug 2015 | diabetes mellitus, hypoglycemia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01994746 | Nov 2013 → Jan 2015 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01959334 | Sep → Dec 2013 | diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00740324 | Aug 2008 → Mar 2009 | — | Nihon Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT00206258 | Jul 2002 → Aug 2005 | type 1 diabetes mellitus | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 49 trials | ||||||
| Phase 4 | NCT06986603 | Nov 2024 → Jun 2026 overdue | hypoglycemia | Joslin Diabetes Center | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04307797 | Jan → Oct 2022 | obesity disorder, type 2 diabetes mellitus | Cambridge University Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT05206149 | Oct → Dec 2021 | hypopituitarism | A.O.U. Città della Salute e della Scienza | Completed | No outcome recorded |
| Phase 4 | NCT03533179 | Jun 2018 → Oct 2019 | — | University Hospital Bispebjerg and Frederiksberg | Completed | No outcome recorded |
| Phase 4 | NCT02516150 | Mar 2016 → May 2017 | type 1 diabetes mellitus | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02232971 | Sep 2014 → Jan 2015 | type 1 diabetes mellitus | Hvidovre University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01674283 | Oct 2013 | female infertility | Clinique Ovo | Withdrawn | No outcome recorded |
| Phase 4 | NCT01155206 | Jun 2009 → Jan 2010 | diabetes mellitus | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 4 | NCT00155376 | Sep 2005 | liver disorder | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase not applicable15 trials | ||||||
| — | NCT06872060 | Jun 2026 → Nov 2027 expected | kidney disorder | Bispebjerg Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07366710 | Nov 2024 → Oct 2027 expected | NAFLD1, glucose metabolism disease | Rigshospitalet, Denmark | Active not recruiting | No outcome recorded |
| — | NCT05379686 | Sep 2022 → May 2024 | hypoglycemia, type 1 diabetes mellitus | Steno Diabetes Center Copenhagen | Completed | No outcome recorded |
| — | NCT05076292 | Nov 2021 → Aug 2023 | hypoglycemia, type 1 diabetes mellitus | Steno Diabetes Center Copenhagen | Completed | No outcome recorded |
| — | NCT04859322 | Feb → Dec 2021 | NAFLD1 | Malte Palm Suppli, MD | Completed | No outcome recorded |
| — | NCT05056584 | Aug 2020 → Mar 2023 | abnormality of glucagon secretion, chronic kidney disease, cirrhosis of liver | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
| — | NCT05095259 | Dec 2019 → Dec 2023 | type 1 diabetes mellitus | Nordsjaellands Hospital | Unknown | No outcome recorded |
| — | NCT03970772 | Apr → Jun 2019 | hypoglycemia, type 1 diabetes mellitus | Qassim University | Completed | No outcome recorded |
| — | NCT02882737 | Sep 2016 → Jul 2017 | type 1 diabetes mellitus | Hvidovre University Hospital | Completed | No outcome recorded |
| — | NCT02475421 | May 2015 → Dec 2016 | diabetes mellitus | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
| — | NCT01935791 | Jul 2013 → Nov 2018 | metabolic disease | Imperial College London | Completed | No outcome recorded |
| — | NCT01795235 | Dec 2012 → Jul 2014 | — | University of Virginia | Unknown | No outcome recorded |
| — | NCT01680653 | May → Sep 2012 | type 1 diabetes mellitus | Stanford University | Completed | No outcome recorded |
| — | NCT01483651 | Nov 2011 → Mar 2013 | type 1 diabetes mellitus | Legacy Health System | Completed | No outcome recorded |
| — | NCT01986231 | Jan 2011 → Dec 2012 | type 1 diabetes mellitus | Legacy Health System | Completed | No outcome recorded |
Also used as a comparator or background therapy in 38 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 116 trials | ||||||
| Phase 1 | NCT06558422 Background | Jan 2027 → Dec 2028 expected | hyperinsulinism, metabolic dysfunction-associated steatotic liver disease, obesity disorder, prediabetes syndrome | Columbia University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06126354 Background | Jul 2024 → Nov 2025 | NAFLD1, prediabetes syndrome | Columbia University | Withdrawn | No outcome recorded |
| Phase 1 | NCT05724134 Background | Aug 2023 → Sep 2025 | NAFLD1, hyperinsulinism, obesity disorder, prediabetes syndrome | Columbia University | Completed | No outcome recorded |
| Phase 1 | NCT03765502 Comparator | Nov 2018 → Jan 2019 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03241706 Comparator | Aug 2018 → May 2028 expected | hypoglycemia | Jason Winnick | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03444467 Comparator | Feb → May 2018 | type 1 diabetes mellitus, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03139305 Comparator | Oct 2017 → Feb 2018 overdue | obesity disorder | AdventHealth Translational Research Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02748369 Comparator | Jul 2016 → Mar 2017 | hypermetabolism due to uncoupled mitochondrial oxidative phosphorylation 2 | K. Sreekumaran Nair | Completed | No outcome recorded |
| Phase 1 | NCT02459938 Comparator | Jan → Aug 2015 | hypoglycemia | Zosano Pharma Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02367053 Comparator | Dec 2014 → Apr 2015 | hypoglycemia | Zealand Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02237053 Comparator | Sep 2014 → Jun 2015 | abnormality of glucagon secretion, obesity disorder | AdventHealth Translational Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT01640834 Background | Jul → Sep 2012 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01300260 Background | Feb → Aug 2011 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT00823940 Background | Jan → Apr 2009 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00745186 Comparator | Aug → Oct 2007 | hypoglycemia | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02012166 Background | Jul → Dec 2005 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT05454709 Comparator | Dec 2023 | type 1 diabetes mellitus | Inreda Diabetic B.V. | Withdrawn | No outcome recorded |
| Phase 2 | NCT02490098 Comparator | Jan → Jul 2018 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT02916251 Comparator | Dec 2016 → Apr 2017 | type 1 diabetes mellitus | Zealand Pharma | Completed | No outcome recorded |
| Phase 2 | NCT02798250 Comparator | Jun 2016 → Mar 2017 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02626936 Comparator | Jan → Jun 2016 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02660008 Comparator | Jan → Jun 2016 | hypoglycemia | Zealand Pharma | Completed | No outcome recorded |
| Phase 2 | NCT02416765 Comparator | May → Oct 2015 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT01828125 Comparator | Apr → Dec 2013 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT02846857 Comparator | ? → Jul 2019 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Withdrawn | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02018627 Comparator | Apr 2014 → Aug 2018 | type 1 diabetes mellitus | Steven J. Russell, MD, PhD | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT03667053 Comparator | Sep 2018 → Jun 2019 | hypoglycemia | Zealand Pharma | Completed | No outcome recorded |
| Phase 3 | NCT03378635 Comparator | Dec 2017 → Apr 2018 | hypoglycemia, type 1 diabetes mellitus | Zealand Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00929812 Comparator | Jun 2006 → Jan 2008 | obesity disorder, type 1 diabetes mellitus | Charite University, Berlin, Germany | Unknown | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT07427251 Comparator | Mar 2026 → May 2027 expected | type 1 diabetes mellitus | Steno Diabetes Center Copenhagen | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04949867 Comparator | May 2021 → Apr 2022 | type 1 diabetes mellitus | Steno Diabetes Center Copenhagen | Completed | No outcome recorded |
| Phase 4 | NCT04053712 Comparator | Jul 2019 → Mar 2021 | hypoglycemia, type 1 diabetes mellitus | Steno Diabetes Center Copenhagen | Completed | No outcome recorded |
| Phase 4 | NCT02078726 Comparator | Apr 2014 → May 2018 | colon carcinoma | University of California, San Francisco | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT03835013 Comparator | Feb 2019 → Nov 2021 | cardiovascular disorder | Cambridge University Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| — | NCT03526445 Comparator | May 2018 → Jun 2019 | NAFLD1, diabetes mellitus | Steno Diabetes Center Copenhagen | Completed | No outcome recorded |
| — | NCT03217175 Comparator | Aug 2017 → Mar 2018 | type 1 diabetes mellitus | Massachusetts General Hospital | Terminated | No outcome recorded |
| — | NCT03061227 Comparator | Feb 2017 → Jan 2019 | diabetes mellitus, metabolic syndrome X | University Hospital Tuebingen | Completed | No outcome recorded |
| — | NCT00005889 Background | Oct 1999 → ? | hyperglycemia | National Center for Research Resources (NCRR) | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-03-24 | Novo Nordisk A/S | The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist novonordisk.com ↗ |
Evidence & citations 28 cited values
Every value below carries the sentence it was read from. 115 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | glucagon | “Exploratory Study of Additional Use of Scopolamine Butylbromide, Glucagon or NPO-11 Following Single Dose of NPO-11 in Healthy Adult Men” NCT00740324 ↗105“Intranasal glucagon is administered at the dose of 3 mg. This corresponds to the administration of a single dose of Baqsimi®.” NCT05206149 ↗ “1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector” NCT03738865 ↗ “A solution of 5 ng glucagon /Unit Lyumjev is injcetd subcutaneously” NCT06854861 ↗ “BIOD-961 is a lyophilized glucagon formulation.” NCT02403648 ↗ “native glucagon” NCT03667053 ↗ “glucagon” NCT02459938 ↗ “Glucagon” NCT05500586 ↗ |
| Known as | Baqsimi | “The main purpose of this study is to evaluate the safety and tolerability of a study drug called nasal glucagon (Baqsimi) in pediatric participants with type 1 diabetes (T1D)...” NCT04992312 ↗ |
| Known as | BC Glucagon | “BioChaperone® Glucagon (BC Glucagon) formulation 1” NCT03176524 ↗ |
| Known as | BIOD-961 | “BIOD-961 is a lyophilized glucagon formulation.” NCT02403648 ↗ |
| Known as | Dry-Mist nasal glucagon | “Dry-Mist nasal glucagon” NCT02402933 ↗ |
| Known as | G-Pen | “receive 1 mg G-Pen (glucagon injection) during one episode and 1 mg Lilly Glucagon during the other episode.” NCT02656069 ↗1“1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector” NCT03738865 ↗ |
| Known as | G-Pen (glucagon injection) | “G-Pen™ (glucagon injection)” NCT02423980 ↗1“G-Pen (glucagon injection)” NCT03091673 ↗ |
| Known as | G-Pen Mini | “G-Pen Mini™ (glucagon injection)” NCT02081014 ↗ |
| Known as | G-Pump | “0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump” NCT02733588 ↗ |
| Known as | GlucaGen | “Glucagon (GlucaGen)” NCT02459938 ↗ |
| Known as | GlucaGen HypoKit | “Drug: GlucaGen HypoKit” NCT03667053 ↗ |
| Known as | Glucagon for Injection | “a freshly reconstituted formulation of glucagon that has poor stability in solution, Glucagon for Injection (Eli Lilly)” NCT02018627 ↗ |
| Known as | Glucagon RTU | “Glucagon RTU is a sterile subcutaneous injectable non-aqueous solution formulation supplied in a vial and administered via syringe.” NCT03770637 ↗ |
| Known as | Gvoke HypoPen | “A ready-to-use, liquid stable glucagon, administered subcutaneously by glucagon autoinjector (GAI), Gvoke HypoPen (glucagon injection; Xeris Pharmaceuticals), was evaluated for...” PMID 34620618 ↗ Oct 2021 |
| Known as | ING | “AIM: To investigate the specific effects of intranasal glucagon (ING) on plasma glucose, endogenous glucose production (EGP) and lipid concentration.” PMID 28730676 ↗ Sep 2017 |
| Known as | Lilly Glucagon | “receive 1 mg G-Pen (glucagon injection) during one episode and 1 mg Lilly Glucagon during the other episode.” NCT02656069 ↗1“Lilly glucagon 30 micrograms, subcutaneous injection” NCT02018627 ↗ |
| Known as | LY900018 | “A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes” NCT04992312 ↗ |
| Known as | MDG | “subcutaneously-given mini-dose glucagon (MDG) as an alternative to carbohydrate consumption” NCT03970772 ↗ |
| Known as | mini-dose glucagon | “mini-dose glucagon” NCT02660242 ↗ |
| Known as | Mini-glucagon | “Drug: Mini-glucagon” NCT01680653 ↗ |
| Known as | Native glucagon | “Glucagon (Native glucagon)” NCT02916251 ↗ |
| Known as | Novo Glucagon | “1 mg subcutaneous injection of Novo Glucagon (glucagon injection)” NCT03738865 ↗ |
| Known as | Xeris glucagon | “Xeris glucagon 50 micrograms, subcutaneous injection” NCT02018627 ↗ |
| Known as | Xerisol Glucagon | “XeriSol glucagon is an investigational drug that is a stable, soluble liquid glucagon formulation that can be injected or administered through an insulin pump.” NCT03424044 ↗1“micro-doses of a new formulation of stable glucagon, Xerisol Glucagon (Xeris Pharmaceuticals), will be non-inferior” NCT02018627 ↗ |
| Known as | ZP-Glucagon | “Glucagon (ZP-Glucagon)” NCT02459938 ↗ |
| Action | Restore | “supplementing glucagon in the late postprandial period” PMID 15793249 ↗ Apr 2005 |
| Modality | Peptide | “synthetic glucagon peptide” NCT02937558 ↗ |
| Route | Intravenous | “glucagon IV for 24 hours” NCT00005889 ↗ |